Chemotherapy

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Early Identification of Chemotherapy Induced Cardiac Toxicity

   Rochester, Minn.

   The purpose of this study is to determine whether changes in the following parameters of cardiac function with low intensity exercise occur following anthracycline therapy:

   • 2D and 3D left ventricular (LV) longitudinal strain and strain rate
   • Right ventricular (RV) longitudinal strain and strain rate
   • LV circumferential and radial strain and strain rate
   • 2D and 3D wall motion
   • 2D and 3D volumetric LVEF
   • Mitral valve inflow velocities (E, A) and mitral annular tissue Doppler (e’, a’)
   • Tricuspid tissue velocities and TAPSE

   The study will also determine whether changes after chemotherapy in any of the aforementioned parameters of cardiac function with low intensity exercise:

   • Occur before changes in resting strain or resting LVEF
   • Predict future reductions in LVEF (cardiotoxicity)
   • Predict the development of clinical heart failure

    

2. A Study of the Safety and Effectiveness of Nivolumab in Combination with Brentuximab Vedotin to Treat Non-Hodgkin's Lymphoma

   Rochester, Minn.

   The purpose of this study is to assess the safety and effectiveness of nivolumab combined with brentuximab to treat patients with certain subtypes of non-Hodgkin's lymphoma.

3. A Study to See if Ultrasound Shear Wave Elastography Can Find Early Heart Muscle Damage from Chemotherapy in Cancer Patients

   Rochester, Minn.

   The purpose of this study is see if a new ultrasound-based technique similar to standard clinical echocardiography, called Shear Wave Elastography, can provide reliable early detection of heart muscle damage caused by chemotherapy.

4. Fat Emulsion in Preventing Hypersensitivity Reactions in Patients With Cancer Receiving Carboplatin or Oxaliplatin

   Rochester, Minn.

   This randomized pilot trial studies how well fat emulsion works in preventing hypersensitivity reactions in patients with cancer receiving carboplatin or oxaliplatin. Giving lipids before chemotherapy may prevent some drug reactions from carboplatin or oxaliplatin.

5. Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

   Rochester, Minn.

   This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are eligible for stem cell transplant. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab, lenalidomide, and dexamethasone may work better in treating patients with multiple myeloma.

6. A Study Comparing X-396 (Ensartinib) to Crizotinib in Patients with ALK Positive Non-Small Cell Lung Cancer

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the effectiveness and safety of X-396 (ensartinib) versus crizotinib in patients who have ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.

7. Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

   Rochester, Minn.

   This randomized phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn't get any anthracycline chemotherapy. Heart failure happens when the heart muscle has been weakened and can't pump blood as well as it should. Carvedilol may help lower the risk of cardiovascular complications.

8. A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer

   Rochester, Minn.

   The purpose of this study is to evaluate the anti-tumor activity and safety of avelumab in combination with axitinib compared to sunitinib alone, when given as a first-line treatment, to patients with advanced renal cell cancer.

9. A Study to Collect and Correlate the Data from Multiple Risk Assessments for Heart Toxicity in Patients Receiving Chemotherapy for Breast Cancer

   Rochester, Minn.

   The purpose of this study is to collect and correlate the data from various cardiovascular risk asessments to successfully measure the risk of heart toxicity in patients receiving chemotherapy for breast cancer.

10. Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

    Scottsdale/Phoenix, Ariz., Rochester, Minn.

    This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib or carfilzomib together with lenalidomide and dexamethasone may kill more cancer cells